252 related articles for article (PubMed ID: 30253201)
21. [Development of Microphysiological Systems (MPSs) Based on Microfluidic Technology for Drug Discovery in Japan].
Kimura H
Yakugaku Zasshi; 2023; 143(1):39-44. PubMed ID: 36596538
[TBL] [Abstract][Full Text] [Related]
22. An isogenic blood-brain barrier model comprising brain endothelial cells, astrocytes, and neurons derived from human induced pluripotent stem cells.
Canfield SG; Stebbins MJ; Morales BS; Asai SW; Vatine GD; Svendsen CN; Palecek SP; Shusta EV
J Neurochem; 2017 Mar; 140(6):874-888. PubMed ID: 27935037
[TBL] [Abstract][Full Text] [Related]
23. Reverse engineering human neurodegenerative disease using pluripotent stem cell technology.
Liu Y; Deng W
Brain Res; 2016 May; 1638(Pt A):30-41. PubMed ID: 26423934
[TBL] [Abstract][Full Text] [Related]
24. Usefulness of a humanized tricellular static transwell blood-brain barrier model as a microphysiological system for drug development applications. - A case study based on the benchmark evaluations of blood-brain barrier microphysiological system.
Nakayama-Kitamura K; Shigemoto-Mogami Y; Toyoda H; Mihara I; Moriguchi H; Naraoka H; Furihata T; Ishida S; Sato K
Regen Ther; 2023 Mar; 22():192-202. PubMed ID: 36891355
[TBL] [Abstract][Full Text] [Related]
25. Human iPSC-based cardiac microphysiological system for drug screening applications.
Mathur A; Loskill P; Shao K; Huebsch N; Hong S; Marcus SG; Marks N; Mandegar M; Conklin BR; Lee LP; Healy KE
Sci Rep; 2015 Mar; 5():8883. PubMed ID: 25748532
[TBL] [Abstract][Full Text] [Related]
26. Microphysiological Blood-Brain Barrier Systems for Disease Modeling and Drug Development.
Mulay AR; Hwang J; Kim DH
Adv Healthc Mater; 2024 Mar; ():e2303180. PubMed ID: 38430211
[TBL] [Abstract][Full Text] [Related]
27. Human inducible pluripotent stem cells: Realization of initial promise in drug discovery.
Kleiman RJ; Engle SJ
Cell Stem Cell; 2021 Sep; 28(9):1507-1515. PubMed ID: 34478628
[TBL] [Abstract][Full Text] [Related]
28. Modeling Neurovascular Disorders and Therapeutic Outcomes with Human-Induced Pluripotent Stem Cells.
Bosworth AM; Faley SL; Bellan LM; Lippmann ES
Front Bioeng Biotechnol; 2017; 5():87. PubMed ID: 29441348
[TBL] [Abstract][Full Text] [Related]
29. The relevance and potential roles of microphysiological systems in biology and medicine.
Wikswo JP
Exp Biol Med (Maywood); 2014 Sep; 239(9):1061-72. PubMed ID: 25187571
[TBL] [Abstract][Full Text] [Related]
30. Translation of Human-Induced Pluripotent Stem Cells: From Clinical Trial in a Dish to Precision Medicine.
Sayed N; Liu C; Wu JC
J Am Coll Cardiol; 2016 May; 67(18):2161-2176. PubMed ID: 27151349
[TBL] [Abstract][Full Text] [Related]
31. Tissue Chips to aid drug development and modeling for rare diseases.
Low LA; Tagle DA
Expert Opin Orphan Drugs; 2016; 4(11):1113-1121. PubMed ID: 28626620
[TBL] [Abstract][Full Text] [Related]
32. Activation of RARα, RARγ, or RXRα Increases Barrier Tightness in Human Induced Pluripotent Stem Cell-Derived Brain Endothelial Cells.
Stebbins MJ; Lippmann ES; Faubion MG; Daneman R; Palecek SP; Shusta EV
Biotechnol J; 2018 Feb; 13(2):. PubMed ID: 28960887
[TBL] [Abstract][Full Text] [Related]
33. Barrier Properties and Transcriptome Expression in Human iPSC-Derived Models of the Blood-Brain Barrier.
Delsing L; Dönnes P; Sánchez J; Clausen M; Voulgaris D; Falk A; Herland A; Brolén G; Zetterberg H; Hicks R; Synnergren J
Stem Cells; 2018 Dec; 36(12):1816-1827. PubMed ID: 30171748
[TBL] [Abstract][Full Text] [Related]
34. 3D Engineering of Ocular Tissues for Disease Modeling and Drug Testing.
Boutin ME; Hampton C; Quinn R; Ferrer M; Song MJ
Adv Exp Med Biol; 2019; 1186():171-193. PubMed ID: 31654390
[TBL] [Abstract][Full Text] [Related]
35. Advancing drug discovery for neuropsychiatric disorders using patient-specific stem cell models.
Haggarty SJ; Silva MC; Cross A; Brandon NJ; Perlis RH
Mol Cell Neurosci; 2016 Jun; 73():104-15. PubMed ID: 26826498
[TBL] [Abstract][Full Text] [Related]
36. 3D human brain cell models: New frontiers in disease understanding and drug discovery for neurodegenerative diseases.
Korhonen P; Malm T; White AR
Neurochem Int; 2018 Nov; 120():191-199. PubMed ID: 30176269
[TBL] [Abstract][Full Text] [Related]
37. Microfluidic blood-brain barrier model provides in vivo-like barrier properties for drug permeability screening.
Wang YI; Abaci HE; Shuler ML
Biotechnol Bioeng; 2017 Jan; 114(1):184-194. PubMed ID: 27399645
[TBL] [Abstract][Full Text] [Related]
38. Huntington's Disease iPSC-Derived Brain Microvascular Endothelial Cells Reveal WNT-Mediated Angiogenic and Blood-Brain Barrier Deficits.
Lim RG; Quan C; Reyes-Ortiz AM; Lutz SE; Kedaigle AJ; Gipson TA; Wu J; Vatine GD; Stocksdale J; Casale MS; Svendsen CN; Fraenkel E; Housman DE; Agalliu D; Thompson LM
Cell Rep; 2017 May; 19(7):1365-1377. PubMed ID: 28514657
[TBL] [Abstract][Full Text] [Related]
39. [MPS for Blood Brain Barrier].
Sato K; Matsusaki M
Yakugaku Zasshi; 2023; 143(1):45-53. PubMed ID: 36596539
[TBL] [Abstract][Full Text] [Related]
40. Stem cell-based Lung-on-Chips: The best of both worlds?
Nawroth JC; Barrile R; Conegliano D; van Riet S; Hiemstra PS; Villenave R
Adv Drug Deliv Rev; 2019 Feb; 140():12-32. PubMed ID: 30009883
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
